Product Information: Application form (FDA 356h), labeling, patent certifications, user fee information (GDUFA), and cover letter.

Module 2 – CTD Summaries: Quality overall summary (QOS) and bioequivalence summary.

Module 3 – Quality (CMC): Drug substance and drug product information, manufacturing process, specifications, analytical methods, validation reports, and stability data.

Module 4 – Nonclinical (Not required for ANDAs): Generally not applicable unless required by FDA.

Module 5 – Clinical/Bioequivalence: Bioequivalence study reports, statistical analysis, and comparative data.

Completeness Assessment and Filing Review

Upon receipt of the ANDA, the FDA performs a completeness assessment to ensure all necessary data and formats are present. This includes:

• Electronic Technical Validation (via ESG)
• Initial completeness check by the Office of Generic Drugs (OGD)
• Filing communication issued within 60 days (Filing Review Decision)

If the ANDA is accepted for filing, the FDA initiates a 10-month review clock (standard) or a shorter timeline for priority generics.

Data Requirements, Regulatory Expectations, and Approval Timelines

Bioequivalence Data and In Vivo Studies

One of the most critical sections in an ANDA is the demonstration of bioequivalence (BE) to the Reference Listed Drug (RLD). This is often established via:

• Single-dose fasting and fed bioequivalence studies
• Steady-state studies (if required)
• In vitro dissolution profile comparisons (where applicable)

The BE study must show that the 90% confidence intervals for the ratio of test to reference product (in terms of AUC and Cmax) fall within the 80–125% acceptance range.

Labeling and Patent Certification (Paragraph I–IV)

The labeling submitted in Module 1 must be essentially the same as the RLD, with permissible differences such as manufacturer name, inactive ingredients, or packaging.

The applicant must also include patent certifications for Orange Book-listed patents:

• Paragraph I: No patent listed
• Paragraph II: Patent has expired
• Paragraph III: Will wait for patent expiry
• Paragraph IV: Patent is invalid or not infringed (may trigger litigation and 180-day exclusivity)

Drug Master File (DMF) Cross-Reference

If the API is sourced from an external supplier, the applicant must include a DMF Letter of Authorization (LOA) to cross-reference the API manufacturer’s DMF. The DMF should include:

• Route of synthesis
• Impurity profile and specifications
• Stability data and retest period
• Analytical procedures

FDA may issue deficiencies if the referenced DMF is outdated or non-compliant.

CMC and Stability Data Requirements

The Chemistry, Manufacturing, and Controls (CMC) section must be comprehensive and aligned with ICH Q8–Q10 standards. Key expectations include:

• Specifications for drug substance and drug product
• Control of critical process parameters (CPPs)
• Analytical method validation
• Accelerated and long-term stability data covering 6–12 months

Data must demonstrate that the generic product meets all quality attributes over the intended shelf-life.

Facility Inspections and Pre-Submission Facility Correspondence (PFC)

The applicant must ensure that all manufacturing and testing sites are listed correctly and ready for GMP inspections. A Pre-Submission Facility Correspondence (PFC) is required for first-cycle review eligibility.

The FDA conducts site inspections during the review cycle and may issue Form 483 or Warning Letters if deficiencies are observed.

GDUFA Fees and Review Timelines

Generic Drug User Fee Amendments (GDUFA) apply to all ANDAs. These include:

• Application fee
• Facility fees (API and FDF sites)
• DMF fee (paid by DMF holder)

The standard ANDA review goal is 10 months. Priority review (e.g., for sole-source generics) may reduce this to 8 months or less.

ANDA Approval Letter and Final Steps

Once the application is deemed approvable, the FDA issues either:

• Approval Letter: If all requirements are met
• Tentative Approval: If scientific review is complete but marketing is blocked by exclusivity or patent

Applicants must submit final labeling in SPL format and update electronic listings in DailyMed prior to product launch.

Conclusion: Getting Ready for a Compliant ANDA

A successful ANDA submission requires a thorough understanding of regulatory expectations, robust documentation of bioequivalence and CMC data, and early engagement with third-party suppliers and contract manufacturing organizations (CMOs).

Sponsors should monitor FDA’s Drugs@FDA and Orange Book regularly, and refer to Product-Specific Guidances (PSGs) for designing bioequivalence studies. With increasing competition in the generics space, completeness and compliance from the first submission cycle are critical to ensure timely approvals.